JP2005170796A - タンパク質間の新規相互作用及び新規相互作用を利用した廃用性筋萎縮治療剤又は廃用性筋萎縮に係わる方法。 - Google Patents
タンパク質間の新規相互作用及び新規相互作用を利用した廃用性筋萎縮治療剤又は廃用性筋萎縮に係わる方法。 Download PDFInfo
- Publication number
- JP2005170796A JP2005170796A JP2003408744A JP2003408744A JP2005170796A JP 2005170796 A JP2005170796 A JP 2005170796A JP 2003408744 A JP2003408744 A JP 2003408744A JP 2003408744 A JP2003408744 A JP 2003408744A JP 2005170796 A JP2005170796 A JP 2005170796A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- interaction
- awp1
- znf216
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003993 interaction Effects 0.000 title claims abstract description 63
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 35
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 33
- 230000006916 protein interaction Effects 0.000 title abstract description 11
- 208000020538 atrophic muscular disease Diseases 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 122
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 95
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims abstract description 50
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims abstract description 50
- 108010068086 Polyubiquitin Proteins 0.000 claims abstract description 37
- 102100037935 Polyubiquitin-C Human genes 0.000 claims abstract description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 238000012216 screening Methods 0.000 claims abstract description 16
- 238000003745 diagnosis Methods 0.000 claims abstract description 12
- 239000003550 marker Substances 0.000 claims abstract description 12
- 206010028289 Muscle atrophy Diseases 0.000 claims description 35
- 201000000585 muscular atrophy Diseases 0.000 claims description 28
- 230000014509 gene expression Effects 0.000 claims description 23
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 101000782077 Homo sapiens AN1-type zinc finger protein 5 Proteins 0.000 abstract description 93
- 101000782083 Homo sapiens AN1-type zinc finger protein 6 Proteins 0.000 abstract description 93
- 102100036610 AN1-type zinc finger protein 5 Human genes 0.000 abstract description 92
- 102100036605 AN1-type zinc finger protein 6 Human genes 0.000 abstract description 92
- 238000011156 evaluation Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 241001430294 unidentified retrovirus Species 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 210000003205 muscle Anatomy 0.000 description 17
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000009368 gene silencing by RNA Effects 0.000 description 12
- 239000013600 plasmid vector Substances 0.000 description 12
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 11
- 230000020763 muscle atrophy Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 210000004748 cultured cell Anatomy 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 102000005720 Glutathione transferase Human genes 0.000 description 8
- 108010070675 Glutathione transferase Proteins 0.000 description 8
- 208000029578 Muscle disease Diseases 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 102000044159 Ubiquitin Human genes 0.000 description 7
- 108090000848 Ubiquitin Proteins 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000002797 proteolythic effect Effects 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 6
- 102100037204 Sal-like protein 1 Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000004850 protein–protein interaction Effects 0.000 description 6
- 208000021642 Muscular disease Diseases 0.000 description 5
- 201000009623 Myopathy Diseases 0.000 description 5
- 108091081021 Sense strand Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012502 risk assessment Methods 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 3
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 3
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011537 solubilization buffer Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 108010020195 FLAG peptide Proteins 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710185494 Zinc finger protein Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000018700 F-Box Proteins Human genes 0.000 description 1
- 108010066805 F-Box Proteins Proteins 0.000 description 1
- 102100040669 F-box only protein 32 Human genes 0.000 description 1
- 101710191029 F-box only protein 32 Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000610537 Homo sapiens Prokineticin-1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101001129076 Homo sapiens Serine/threonine-protein kinase N1 Proteins 0.000 description 1
- 101000801040 Homo sapiens Transmembrane channel-like protein 1 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037469 Protein DEPP1 Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 description 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
- 102100033690 Transmembrane channel-like protein 1 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000006174 autosomal recessive nonsyndromic deafness 7 Diseases 0.000 description 1
- 208000032445 autosomal recessive nonsyndromic hearing loss 7 Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000025185 skeletal muscle atrophy Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
【解決手段】 プロテアソームとZNF216(又は、AWP1)との間にタンパク質間相互作用があることがわかった。また、ポリユビキチン鎖とZNF216(又はAWP1)との間にもタンパク質間相互作用があることがわかった。この新規なタンパク質間相互作用を利用して、廃用性筋萎縮の治療剤、及び、廃用性筋萎縮治療剤のスクリーニング方法、疾病診断用マーカー、発症リスク評価方法等を提供する。
Description
「実験医学」,羊土社,2003年2月,第21巻,第3号,p.330−332 Gomes et al" Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy",Proc.Natl.Acad.Sci.USA,2000,Vol.98,No.25,pp14440-14445 Bodine et al"Identification of ubiquitin ligases required for skeletal muscle atrophy",Science,2001,Vol.294,pp.1704-1708 D.A.Ccott et al"Identification and mutation analysis of a cochlear-expressed, zinc finger protein gene at the DFNB7/11 and dn hearing-loss-loci on human chromosome 9q and mouse chromosome 19",AN INTERNATIONAL JOURNAL ON GENES AND GENOMES,Elsevier Science B.V.,1998,p461-469 W.Duan et al "Cloning and characterization of AWP1, a novel protein that associates with serine/threonine kinase PRK1 in vivo", AN INTERNATIONAL JOURNAL ON GENES, GENOMES AND EVOLUTION, Elsevier Science B.V.,2000,p113-121
Claims (13)
- プロテアソームと相互作用する性質を有することを特徴とする配列番号1又は配列番号2からなるタンパク質。
- ポリユビキチン鎖と相互作用する性質を有することを特徴とする配列番号1又は配列番号2からなるタンパク質。
- 配列番号1又は配列番号2からなるタンパク質の発現又は機能を抑制することを特徴とする廃用性筋萎縮治療剤。
- 配列番号1又は配列番号2からなるタンパク質とプロテアソームとの相互作用を抑制することを特徴とする廃用性筋萎縮治療剤。
- 配列番号1又は配列番号2からなるタンパク質とポリユビキチン鎖の相互作用を抑制することを特徴とする廃用性筋萎縮治療剤。
- 廃用性筋萎縮治療剤製造のための、配列番号1又は配列番号2からなるタンパク質とプロテアソームとの間の相互作用の使用。
- 配列番号1又は配列番号2からなるタンパク質とプロテアソームとの間の相互作用を利用することを特徴とする廃用性筋萎縮治療剤のスクリーニング方法。
- 配列番号1又は配列番号2からなるタンパク質とプロテアソームとの間の相互作用を利用することを特徴とする廃用性筋萎縮の疾病診断用マーカー。
- 配列番号1又は配列番号2からなるタンパク質とプロテアソームとの間の相互作用を利用することを特徴とする廃用性筋萎縮の発症リスク評価方法。
- 廃用性筋萎縮治療剤製造のための、配列番号1又は配列番号2からなるタンパク質とポリユビキチン鎖との間の相互作用の使用。
- 配列番号1又は配列番号2からなるタンパク質とポリユビキチン鎖との間の相互作用を利用することを特徴とする廃用性筋萎縮治療剤のスクリーニング方法。
- 配列番号1又は配列番号2からなるタンパク質とポリユビキチン鎖との間の相互作用を利用することを特徴とする廃用性筋萎縮の疾病診断用マーカー。
- 配列番号1又は配列番号2からなるタンパク質とポリユビキチン鎖との間の相互作用を利用することを特徴とする廃用性筋萎縮の発症リスク評価方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003408744A JP4399590B2 (ja) | 2003-12-08 | 2003-12-08 | 廃用性筋萎縮治療剤のスクリーニング方法 |
US10/581,969 US7700362B2 (en) | 2003-12-08 | 2004-12-07 | Method for screening therapeutic agents for disuse muscular atrophy using interaction between selected proteins and a polyubiquitin chain |
PCT/JP2004/018179 WO2005056590A1 (ja) | 2003-12-08 | 2004-12-07 | タンパク質間の新規相互作用及び新規相互作用を利用した廃用性筋萎縮治療剤又は廃用性筋萎縮に係わる方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003408744A JP4399590B2 (ja) | 2003-12-08 | 2003-12-08 | 廃用性筋萎縮治療剤のスクリーニング方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005170796A true JP2005170796A (ja) | 2005-06-30 |
JP4399590B2 JP4399590B2 (ja) | 2010-01-20 |
Family
ID=34674885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003408744A Expired - Lifetime JP4399590B2 (ja) | 2003-12-08 | 2003-12-08 | 廃用性筋萎縮治療剤のスクリーニング方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US7700362B2 (ja) |
JP (1) | JP4399590B2 (ja) |
WO (1) | WO2005056590A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007037482A1 (ja) * | 2005-09-30 | 2007-04-05 | The University Of Tokyo | 真核細胞におけるタンパク質-タンパク質相互作用を検出するためのキットと方法 |
WO2017034173A1 (ko) * | 2015-08-27 | 2017-03-02 | 울산대학교 산학협력단 | Awp1을 포함하는 암 전이 진단용 바이오마커 조성물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817494A (en) * | 1997-05-21 | 1998-10-06 | Incyte Pharmaceuticals, Inc. | Ubiquitin conjugation proteins |
WO2000077255A1 (en) * | 1999-06-11 | 2000-12-21 | Human Genome Sciences, Inc. | 49 human secreted proteins |
-
2003
- 2003-12-08 JP JP2003408744A patent/JP4399590B2/ja not_active Expired - Lifetime
-
2004
- 2004-12-07 US US10/581,969 patent/US7700362B2/en not_active Expired - Fee Related
- 2004-12-07 WO PCT/JP2004/018179 patent/WO2005056590A1/ja active Application Filing
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007037482A1 (ja) * | 2005-09-30 | 2007-04-05 | The University Of Tokyo | 真核細胞におけるタンパク質-タンパク質相互作用を検出するためのキットと方法 |
WO2017034173A1 (ko) * | 2015-08-27 | 2017-03-02 | 울산대학교 산학협력단 | Awp1을 포함하는 암 전이 진단용 바이오마커 조성물 |
KR20170025048A (ko) | 2015-08-27 | 2017-03-08 | 울산대학교 산학협력단 | Awp1을 포함하는 암 전이 진단용 바이오마커 조성물 |
KR101821455B1 (ko) | 2015-08-27 | 2018-01-25 | 울산대학교 산학협력단 | Awp1을 포함하는 암 전이 진단용 바이오마커 조성물 |
Also Published As
Publication number | Publication date |
---|---|
WO2005056590A1 (ja) | 2005-06-23 |
JP4399590B2 (ja) | 2010-01-20 |
US7700362B2 (en) | 2010-04-20 |
US20080227694A1 (en) | 2008-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
VanDemark et al. | Autoregulation of the rsc4 tandem bromodomain by gcn5 acetylation | |
Saada et al. | Mutations in NDUFAF3 (C3ORF60), encoding an NDUFAF4 (C6ORF66)-interacting complex I assembly protein, cause fatal neonatal mitochondrial disease | |
Almalki et al. | Mutation of the human mitochondrial phenylalanine-tRNA synthetase causes infantile-onset epilepsy and cytochrome c oxidase deficiency | |
Fall et al. | Genome-wide association studies of obesity and metabolic syndrome | |
US10233495B2 (en) | Methods and compositions for screening and treating developmental disorders | |
Towns et al. | Transfer RNA methytransferases and their corresponding modifications in budding yeast and humans: activities, predications, and potential roles in human health | |
EP2812452B1 (en) | Methods and compositions for screening and treating developmental disorders | |
Sarmento et al. | The worldwide mutational landscape of Berardinelli-Seip congenital lipodystrophy | |
US20180105860A1 (en) | Muteins of the pyrroline-5-carboxylate reductase 1 | |
Tsai et al. | A novel DNAJB6 mutation causes dominantly inherited distal‐onset myopathy and compromises DNAJB6 function | |
Ianzano et al. | Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product | |
Mentrup et al. | A homozygous intronic branch-point deletion in the ALPL gene causes infantile hypophosphatasia | |
Park et al. | Sporadic cardiac and skeletal myopathy caused by a de novo desmin mutation | |
Gray et al. | Engineering a synthetic cell panel to identify signalling components reprogrammed by the cell growth regulator anterior gradient-2 | |
Qi et al. | Androgens differentially regulate the expression of NEDD4L transcripts in LNCaP human prostate cancer cells | |
JP4399590B2 (ja) | 廃用性筋萎縮治療剤のスクリーニング方法 | |
Kronert et al. | Alternative relay domains of Drosophila melanogaster myosin differentially affect ATPase activity, in vitro motility, myofibril structure and muscle function | |
Wang et al. | Cloning, expression and enzyme activity delineation of two novel CANT1 mutations: the disappearance of dimerization may indicate the change of protein conformation and even function | |
Grønbæk-Thygesen et al. | Deep mutational scanning reveals a tight correlation between protein degradation and toxicity of thousands of non-native aspartoacylase protein variants | |
Davydenko et al. | Revision of splicing variants in the DMD gene | |
Abshire et al. | Differential processing and localization of human Nocturnin controls metabolism of mRNA and nicotinamide dinucleotide metabolites | |
Lu et al. | The distal arthrogryposis‐linked p. R63C variant promotes the stability and nuclear accumulation of TNNT3 | |
Norppa et al. | Distinct functions for the paralogous RBM41 and U11/U12-65K proteins in the minor spliceosome | |
Xie | Functional and structural characterization of cytoplasmic poly (A) binding protein | |
Viakhireva et al. | The molecular complexity of COL2A1 splicing variants and their significance in phenotype severity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090826 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090924 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4399590 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121106 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121106 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131106 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
EXPY | Cancellation because of completion of term |